Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Dion J. Weisler, a director of Thermo Fisher Scientific, reported a Section 16 transaction dated 09/27/2025. The filing shows Phantom Stock Units were acquired under the company's Deferred Compensation Plan for Directors and are convertible 1-for-1 into common stock. The report states units were credited at $464.24 per unit and lists 80.78 as the number associated with the reported acquisition and 2,573.95 as the amount of common stock beneficially owned following the transaction. The units are distributable as stock upon cessation of director service or a change of control. The form was signed by an attorney-in-fact on 09/30/2025.
Scott M. Sperling, a director associated with Thomas H. Lee Partners, received 17,428.67 phantom stock units in Thermo Fisher Scientific (TMO) on 09/27/2025 under the company's Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock on a 1-for-1 basis and was credited at a per-unit value of $464.24, reflecting the quarter-end closing price used to calculate director retainer deferrals. The units are distributable as shares when director service ends or if a change of control occurs. The filing documents a grant of stock-linked deferred compensation rather than an open-market purchase or sale.
Keith R. Alexandra, a director of Thermo Fisher Scientific (TMO), reported a grant of 67.31 Phantom Stock Units credited on 09/27/2025 under the company's Deferred Compensation Plan for Directors. The units convert into common stock on a 1-for-1 basis and were credited at a recorded price of $464.24 per unit. The filing shows 1,150.49 shares beneficially owned following the reported transaction. The Plan states deferred director retainers are recorded as common stock units based on quarter-end closing prices and are distributable as stock upon cessation of director service or a change of control. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Karen S. Lynch, a director of Thermo Fisher Scientific (TMO), was credited with 67.31 phantom stock units on 09/27/2025 under the company's Deferred Compensation Plan for Directors. Each unit is convertible 1-for-1 into common stock and was recorded at a deferred unit price of $464.24 per unit. The units are payable as shares upon the director's cessation of service or upon a change of control. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Lynch on 09/30/2025. Following the reported transaction, the filing indicates 171.54 derivative units beneficially owned in a direct form.
Jennifer M. Johnson, a director of Thermo Fisher Scientific Inc. (TMO), was credited with 67.31 Phantom Stock Units on September 27, 2025 under the issuer's Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock on a 1-for-1 basis and the units were credited at a stated price of $464.24 per unit. The units are distributable as stock when the director ceases service or upon a change of control. The filing notes the reporting person is an executive at Franklin Resources, Inc., and that Franklin Templeton subsidiaries may hold Thermo Fisher shares in client accounts; the reporting person disclaims beneficial ownership of those third-party holdings.
Thermo Fisher is offering multiple series of unsecured senior notes to be issued in global book-entry form through DTC, with interest payable semi-annually beginning in 2026. The notes will rank equally with Thermo Fisher's other unsecured senior debt and senior to any subordinated debt; they will be structurally subordinated to subsidiary indebtedness and effectively subordinated to any future secured debt. As of June 28, 2025, Thermo Fisher and its subsidiaries had approximately $35.23 billion of consolidated indebtedness, $5.00 billion of revolver availability and subsidiaries had $6.99 billion of indebtedness to which the notes would be structurally subordinated. The prospectus describes optional redemption mechanics, a 101% repurchase obligation upon a Change of Control Triggering Event, trustee (The Bank of New York Mellon Trust Company, N.A.), governing law (New York) and various tax and withholding provisions. Several specific offering terms (aggregate amounts, coupon rates, exact maturities and some dates) are redacted in the provided text.
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported option exercise and market sales on 09/05/2025 under a Rule 10b5-1 plan. The filing shows the exercise or acquisition of 400 shares at an exercise/conversion price of $253.99 and three market dispositions of 200, 100 and 100 shares at $500, $501 and $501.01 respectively.
Beneficial ownership reported after the transactions is 113,762.285 shares. The report discloses indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust, 14,608 shares by Floral Park Associates, Inc., and 5,000 shares by MNC 2020 Irrevocable Trust. The transactions were effected pursuant to a 10b5-1 trading plan adopted April 28, 2025.
Form 144 filing for Thermo Fisher Scientific, Inc. (TMO) shows an intended sale of 400 shares of common stock through Fidelity Brokerage Services on 09/05/2025, with an aggregate market value listed as $200,201 and the transaction to occur on the NYSE. The 400 shares were acquired by option grant on 02/26/2019 and payment is indicated as cash on 09/05/2025. The filing also discloses recent sales by Marc N. Casper totaling 28,496 shares across five transactions in August 2025, producing gross proceeds of approximately $13.41 million. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Insider transactions by Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO). The Form 4 reports two open-market disposals on 08/28/2025, selling 686.571 shares and 724.767 shares at $489.74 per share. After those sales the filing shows beneficial ownership reported as approximately 114,487.052 and 113,762.285 shares (direct holdings). The filing also discloses indirect holdings of 11,300 shares through the Alison Casper 2020 Irrevocable Trust, 14,608 shares via Floral Park Associates, Inc., and 5,000 shares via the MNC 2020 Irrevocable Trust. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Casper on 09/02/2025.
Thermo Fisher (TMO) Form 4 — insider dispositions by Sr. VP & CFO Stephen Williamson. The filing reports four open-market sales on 08/28/2025 totaling 783.273 shares at $489.74 per share. After these transactions, Williamson directly held 32,320.193 shares and is noted as indirectly beneficially owning 12,674 shares through a SLAT, with a disclaimer that he disclaims beneficial ownership except for any pecuniary interest. The form is signed by an attorney-in-fact on 09/02/2025.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
